Tonix Long Term Debt To Capitalization from 2010 to 2024
| TNXP Stock | USD 0.11 0.04 26.67% |
Check Tonix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tonix Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Tonix financial statements analysis is a perfect complement when working with Tonix Pharmaceuticals Valuation or Volatility modules.
Tonix |
About Tonix Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Tonix Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Tonix Pharmaceuticals investors use historical funamental indicators, such as Tonix Pharmaceuticals's Long Term Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although Tonix Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Tonix Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Tonix Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Tonix Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Tonix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.